AR118787A1 - PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASES - Google Patents
PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASESInfo
- Publication number
- AR118787A1 AR118787A1 ARP190102387A ARP190102387A AR118787A1 AR 118787 A1 AR118787 A1 AR 118787A1 AR P190102387 A ARP190102387 A AR P190102387A AR P190102387 A ARP190102387 A AR P190102387A AR 118787 A1 AR118787 A1 AR 118787A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding
- binding molecules
- molecules
- diseases
- treatment
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente está dirigida a moléculas de unión a PD-L1, tales como anticuerpos monoespecíficos, y fragmentos de unión a epítopo de los mismos, que son capaces de unirse a PD-L1, y a moléculas de unión multiespecíficas (por ejemplo, anticuerpos biespecíficos, diacuerpos biespecíficos, BiTEs, moléculas de unión trivalentes, etc.) que son capaces de unirse tanto a un epítopo de PD-L1 como a un epítopo de CD137 (moléculas de unión a PD-L1 ´ CD137). La presente también se dirige a composiciones farmacéuticas que comprenden tales moléculas. La presente también incluye el uso de tales moléculas en el tratamiento de enfermedades, especialmente cáncer o una enfermedad o afección asociada o caracterizada por la presencia de un sistema inmune suprimido.The present invention is directed to PD-L1 binding molecules, such as monospecific antibodies, and epitope-binding fragments thereof, that are capable of binding to PD-L1, and to multispecific binding molecules (eg, bispecific antibodies, bispecific diabodies, BiTEs, trivalent binding molecules, etc.) that are capable of binding both an epitope of PD-L1 and an epitope of CD137 (PD-L1 ´CD137 binding molecules). The present invention is also directed to pharmaceutical compositions comprising such molecules. The present invention also includes the use of such molecules in the treatment of diseases, especially cancer or a disease or condition associated with or characterized by the presence of a suppressed immune system.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862721984P | 2018-08-23 | 2018-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118787A1 true AR118787A1 (en) | 2021-11-03 |
Family
ID=80053327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190102387A AR118787A1 (en) | 2018-08-23 | 2019-08-22 | PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASES |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR118787A1 (en) |
-
2019
- 2019-08-22 AR ARP190102387A patent/AR118787A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018001485A2 (en) | Bispecific monovalent diabodies that are capable of binding to b7 - h3 and cd3 | |
CO2018005932A2 (en) | Bispecific molecules that have immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
CO2018001149A2 (en) | Monoclonal antibodies against bcma | |
ECSP20024555A (en) | SPECIFIC ANTIBODIES FOR CD47 AND PD-L1 | |
CO2018010538A2 (en) | Specific poliovirus receptor (rvp) antibodies | |
CO2020008940A2 (en) | Gprc5d-binding antibodies | |
CL2017003195A1 (en) | Affinity-matured and humanized antibodies to fcrh5 and methods for their use. | |
CO2017006740A2 (en) | Anti-cd79b antibodies | |
CU20160101A7 (en) | IMMUNOGLOBULINA WITH FAB IN TANDEM | |
EA201891983A8 (en) | COMBINED THERAPY BY ANTIBODIES TO CD73 | |
CL2018001512A1 (en) | Humanized anti-CD73 antibodies. | |
CL2018000744A1 (en) | Anti-tigit antibodies (T lymphocyte immunoreceptor with ig and itim domains) and methods of use. | |
EA201890285A1 (en) | ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
CL2016002547A1 (en) | Antibodies against bispecific her2 | |
CU24533B1 (en) | ANTIBODIES OR FRAGMENTS THEREOF THAT BIND THYMIC STROMAL LYMPHOPOYETIN (TSLP) AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
PE20171764A1 (en) | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES, AND BISPECIFIC ANTIBODIES THAT SPECIFICALLY BIND CD3 AND / OR CD123 | |
CU24498B1 (en) | FACTOR XI ANTIBODIES | |
EA201791050A1 (en) | CONJUGATES OF ANTIBODIES AND MEDICINES | |
EA201790060A1 (en) | BISPECIFIC CD33- and CD3-BINDING PROTEINS | |
UY35042A (en) | ANTI-CD3 ANTIBODIES, BIO-SPECIFIC ANTIGEN MOLECULES THAT JOIN CD3 AND CD20, AND USES OF THE SAME. | |
BR112016014731A2 (en) | ANTI-BAFF ANTIBODIES | |
UY36942A (en) | ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER | |
CO2018012497A2 (en) | Interferon beta antibodies and uses thereof | |
CO2018001010A2 (en) | Monoclonal antibodies specific for the human syncytial respiratory virus (vrsh) antigen, produced and secreted by cellular hybridomas, useful for the detection and diagnosis of infection caused by vrsh | |
CL2019002735A1 (en) | Antibodies that bind to steap-1. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |